GRAY's Business Model
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.graybug.vision |
| CEO (Chief Executive Officer) | Frederic Guerard |
| Number of Employees | |
| IPO date | September 4, 2020 |
GRAY Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 203 Redwood Shores Parkway |
| City | Redwood City |
| State | CA |
| Phone | 650 487 2800 |
| Zip Code | 94065 |
| Other Identifiers | |
| CIK | 0001534133 |
| ISIN | US38942Q1031 |
| CUSIP | 38942Q103 |
| Open | 5.55 |
| Previous Close | 6.1656 |
| Volume | 24.63 Thou. |
| Average Volume | 5.28 Thou. |
| Day’s Range | 5.02 – 6 |
| 52 Week Range | 4.88-20.3 |
| MA (50) | 8.54684 |
| MA (200) | 11.51013 |
| Market Cap | 121 Mil. |
| Shares Out. | 22 Mil. |
| Earnings Date | Aug 09, 2023 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
